To the Editor We congratulate Coats et al1 for their report on the randomized clinical trial of trimetazidine, a direct β-oxidation inhibitor, in patients with nonobstructive hypertrophic cardiomyopathy (HCM). Current therapies for HCM are insufficient, and the search for disease-modifying treatments must be continued. The trimetazidine trial is one of few clinical trials in HCM thus far, to our knowledge. We would like to highlight aspects that may have contributed to the negative outcome of the reported trial.
van Driel B, van der Velden J. Hypertrophic Cardiomyopathy—Need for Gene-Specific Treatment? JAMA Cardiol. 2019;4(8):831–832. doi:10.1001/jamacardio.2019.1752
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: